Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/38529
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorBuendía Rodríguez, Jefferson Antonio-
dc.contributor.authorJustinico Castro, José Armando-
dc.contributor.authorTapia Vela, Laura Joanna-
dc.contributor.authorSinisterra Espejo, Denis María-
dc.contributor.authorSánchez Villamil, Juana Patricia-
dc.contributor.authorZuluaga Salazar, Andrés Felipe-
dc.date.accessioned2024-03-10T01:00:51Z-
dc.date.available2024-03-10T01:00:51Z-
dc.date.issued2019-
dc.identifier.citationBuendía JA, Justinico Castro JA, Vela LJT, Sinisterra D, Sánchez Villamil JP, Zuluaga Salazar AF. Comparison of four pharmacological strategies aimed to prevent the lung inflammation and paraquat-induced alveolar damage. BMC Res Notes. 2019 Sep 18;12(1):584. doi: 10.1186/s13104-019-4598-0.spa
dc.identifier.urihttps://hdl.handle.net/10495/38529-
dc.description.abstractABSTRACT: Objective: The aim of this study was to compare in vivo efect of fve pharmacological options on infammation and pulmonary fbrosis induced by paraquat. Methods: 54 Wistar SPF rats were used. After 2 h post-intoxication with paraquat ion, groups of 9 animals were ran domly assigned to (1) cyclophosphamide plus dexamethasone (2) low molecular weight heparin (3) unfractionated heparin (4) vitamin C every 24 h, (5) atorvastatin or (6) placebo with intraperitoneal saline. Lung infammation, alveolar injury, hepatocyte damage, hepatic regeneration, acute tubular necrosis and kidney congestion were evaluated. Results: In the control group 100% of animals presented moderate and severe lung infammation, while in the groups with atorvastatin and intratracheal heparin this proportion was lower (55.5%; CI 26.6–81.3%) (p=0.025). A lower degree of moderate or severe hepatic regeneration was evident in the treatment groups with atorvastatin (p=0.009). In this study was demonstrated that statins and heparin might have a protective efect in the paraquat induced destructive phase. More evidence is needed to evaluated of dose–response efects of these drugs before to study in clinical trialsspa
dc.format.extent5 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherBMC (BioMed Central)spa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/co/*
dc.titleComparison of four pharmacological strategies aimed to prevent the lung infammation and paraquat-induced alveolar damagespa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGrupo de Investigación en Farmacología y Toxicologíaspa
dc.identifier.doi10.1186/s13104-019-4598-0-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn1756-0500-
oaire.citationtitleBMC Research Notesspa
oaire.citationstartpage1spa
oaire.citationendpage5spa
oaire.citationvolume12spa
oaire.citationissue1spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by/4.0/spa
oaire.fundernameColombia. Ministerio de Ciencia, Tecnología e Innovaciónspa
dc.publisher.placeLondres, Inglaterraspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.subject.decsAntioxidantes - Farmacología-
dc.subject.decsAntioxidants - pharmacology-
dc.subject.decsÁcido Ascórbico - Farmacología-
dc.subject.decsAscorbic Acid - pharmacology-
dc.subject.decsAtorvastatina-
dc.subject.decsAtorvastatin-
dc.subject.decsPulmón-
dc.subject.decsLung-
dc.subject.decsParaquat-
dc.subject.decsCiclofosfamida-
dc.subject.decsCyclophosphamide-
dc.subject.decsDexametasona-
dc.subject.decsDexamethasone-
dc.subject.decsQuimioterapia Combinada-
dc.subject.decsDrug Therapy, Combination-
dc.subject.decsHeparina de Bajo-Peso-Molecular-
dc.subject.decsHeparin, Low-Molecular-Weight-
dc.subject.decsNeumonía-
dc.subject.decsPneumonia-
dc.subject.decsAlveolos Pulmonares-
dc.subject.decsPulmonary Alveoli-
dc.subject.decsFibrosis Pulmonar-
dc.subject.decsPulmonary Fibrosis-
dc.subject.decsRatas Wistar-
dc.subject.decsRats, Wistar-
dc.subject.decsResultado del Tratamiento-
dc.subject.decsTreatment Outcome-
dc.description.researchgroupidCOL0039902spa
oaire.awardnumber833-2015spa
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000975-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D001205-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000069059-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D008168-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D010269-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D003520-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D003907-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D004359-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D006495-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D011014-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D011650-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D011658-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D017208-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D016896-
dc.relation.ispartofjournalabbrevBMC Res. Notes.spa
oaire.funderidentifier.rorRoR:03fd5ne08-
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
BuendiaJefferson_2019_Comparison_Four_Pharmacological_Strategies.pdfArtículo de investigación810.18 kBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons